"Trastuzumab refractory HER2 positive" trang 1 - tải miễn phí từ tailieunhanh
Randomized double-blind clinical trial comparing safety and efficacy of the biosimilar BCD-022 with reference trastuzumab

Randomized double-blind clinical trial comparing safety and efficacy of the biosimilar BCD-022 with reference trastuzumab
10    44    1
Adjuvant trastuzumab duration trials in HER2 positive breast cancer – what results would be practice-changing? Persephone investigator questionnaire prior to primary endpoint results

Adjuvant trastuzumab duration trials in HER2 positive breast cancer – what results would be practice-changing? Persephone investigator questionnaire prior to primary endpoint results
7    55    1
Pro1170 Ala polymorphism in HER2-neu is associated with risk of trastuzumab cardiotoxicity

Pro1170 Ala polymorphism in HER2-neu is associated with risk of trastuzumab cardiotoxicity
7    33    1
Final analysis of the phase 3 randomized clinical trial comparing HD201 vs. referent trastuzumab in patients with ERBB2-positive breast cancer treated in the neoadjuvant setting

Final analysis of the phase 3 randomized clinical trial comparing HD201 vs. referent trastuzumab in patients with ERBB2-positive breast cancer treated in the neoadjuvant setting
9    6    1
Determination of cellular processing rates for a Trastuzumab-Maytansinoid antibody-drug conjugate (ADC) highlights key parameters for ADC design

Determination of cellular processing rates for a Trastuzumab-Maytansinoid antibody-drug conjugate (ADC) highlights key parameters for ADC design
12    83    0
Lapatinib in combination with capecitabine versus continued use of trastuzumab in breast cancer patients with trastuzumabresistance: A retrospective study of a Chinese population

Lapatinib in combination with capecitabine versus continued use of trastuzumab in breast cancer patients with trastuzumabresistance: A retrospective study of a Chinese population
10    35    0
Lacrimal drainage system stenosis associated with Trastuzumab emtansine (Kadcyla®, T-DM1) administration: A case report

Lacrimal drainage system stenosis associated with Trastuzumab emtansine (Kadcyla®, T-DM1) administration: A case report
4    48    0
Two-dimensional speckle tracking echocardiography predicts early subclinical cardiotoxicity associated with anthracycline-trastuzumab chemotherapy in patients with breast cancer

Two-dimensional speckle tracking echocardiography predicts early subclinical cardiotoxicity associated with anthracycline-trastuzumab chemotherapy in patients with breast cancer
8    89    0
Long-term responders to trastuzumab monotherapy in first-line HER-2+ advanced breast cancer: Characteristics and survival data

Long-term responders to trastuzumab monotherapy in first-line HER-2+ advanced breast cancer: Characteristics and survival data
7    77    0
Cancer-derived exosomes from HER2-positive cancer cells carry trastuzumab-emtansine into cancer cells leading to growth inhibition and caspase activation

Cancer-derived exosomes from HER2-positive cancer cells carry trastuzumab-emtansine into cancer cells leading to growth inhibition and caspase activation
12    47    1
Optimal regimen of trastuzumab in combination with oxaliplatin/ capecitabine in first-line treatment of HER2-positive advanced gastric cancer (CGOG1001): A multicenter, phase II trial

Optimal regimen of trastuzumab in combination with oxaliplatin/ capecitabine in first-line treatment of HER2-positive advanced gastric cancer (CGOG1001): A multicenter, phase II trial
9    59    1
Up-regulation of HER2 by gemcitabine enhances the antitumor effect of combined gemcitabine and trastuzumab emtansine treatment on pancreatic ductal adenocarcinoma cells

Up-regulation of HER2 by gemcitabine enhances the antitumor effect of combined gemcitabine and trastuzumab emtansine treatment on pancreatic ductal adenocarcinoma cells
9    50    1
Transcriptional expression of 8 genes predicts pathological response to first-line docetaxel + trastuzumab-based neoadjuvant chemotherapy

Transcriptional expression of 8 genes predicts pathological response to first-line docetaxel + trastuzumab-based neoadjuvant chemotherapy
6    54    1
Quantitative measurements of HER2 and phospho-HER2 expression: Correlation with pathologic response to neoadjuvant chemotherapy and trastuzumab

Quantitative measurements of HER2 and phospho-HER2 expression: Correlation with pathologic response to neoadjuvant chemotherapy and trastuzumab
8    42    1
Sunitinib in combination with trastuzumab for the treatment of advanced breast cancer: Activity and safety results from a phase II study

Sunitinib in combination with trastuzumab for the treatment of advanced breast cancer: Activity and safety results from a phase II study
10    43    1
Long-term tumor remission under trastuzumab treatment for HER2 positive metastatic breast cancer – results from the HER-OS patient registry

Long-term tumor remission under trastuzumab treatment for HER2 positive metastatic breast cancer – results from the HER-OS patient registry
7    39    1
Đánh giá kết quả của hóa trị hỗ trợ kết hợp trastuzumab trong ung thư vú giai đoạn I, II, III có biểu hiện quá mức của Her2

Đánh giá kết quả của hóa trị hỗ trợ kết hợp trastuzumab trong ung thư vú giai đoạn I, II, III có biểu hiện quá mức của Her2
11    45    2
Bước đầu đánh giá hiệu quả hóa trị kết hợp ức chế kép Pertuzumab trastuzumab trong điều trị trước mổ bệnh ung thư vú HER2 (+)

Bước đầu đánh giá hiệu quả hóa trị kết hợp ức chế kép Pertuzumab trastuzumab trong điều trị trước mổ bệnh ung thư vú HER2 (+)
7    62    1
Đánh giá kết quả bước đầu hóa trị vinorelbine kết hợp trastuzumab trên bệnh nhân ung thư vú di căn có HER2 dương tính tại Bệnh viện Quân Y 103

Đánh giá kết quả bước đầu hóa trị vinorelbine kết hợp trastuzumab trên bệnh nhân ung thư vú di căn có HER2 dương tính tại Bệnh viện Quân Y 103
8    34    2
Ado-trastuzumab for the treatment of metastatic HER2-positive breast cancer in patients previously treated with Pertuzumab

Ado-trastuzumab for the treatment of metastatic HER2-positive breast cancer in patients previously treated with Pertuzumab
8    61    1